Header cover image
  • Investing Ideas
  • /
  • Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Results

1

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Newron Pharmaceuticals

Market Cap: CHF 509.0m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

NWRN

CHF 25.50

7D

4.3%

1Y

179.3%